Oncometabolism

Source: Wikipedia, the free encyclopedia.

Oncometabolism is the field of study that focuses on the metabolic changes that occur in cells that make up the tumor microenvironment (TME) and accompany oncogenesis and tumor progression toward a neoplastic state.[1]

Cells with increased growth and survivability differ from non-tumorigenic cells in terms of metabolism.[2] The Warburg Effect, which describes how cancer cells change their metabolism to become more oncogenic in order to proliferate and eventually invade other tissues in a process known as metastasis.[1]

The chemical reactions associated with oncometabolism are triggered by the alteration of

upregulation as a result of DNA damage can result in an overabundance of these metabolites, and lead to tumorigenesis. These metabolites are known as oncometabolites, and can act as biomarkers.[4]

Otto Heinrich Warburg, considered the "Father of Oncometabolism" for his early discoveries in the field

History

In the 1920s, Otto Heinrich Warburg discovered an intriguing bioenergetic phenotype shared by most tumor cells: a higher-than-normal reliance on lactic acid fermentation for energy generation. He is known as the "Father of Oncometabolism".[1][2] Although the roots of this research field trace back to the 1920s, it was only recently recognized[1] Over the last decade, research on cancer progression has focused on the role of shifting metabolic pathways for both the cancer and immune cells, leading to an increase interest in characterizing the metabolic alterations that cells undergo in the TME.[5]

Warburg Effect

In the absence of hypoxic conditions (i.e. physiological levels of oxygen), cancer cells preferentially convert glucose to lactate, according to Otto H. Warburg, who believed that aerobic glycolysis was the key metabolic change in cancer cell malignancy. The "Warburg effect" was later coined to describe this metabolic shift.[6] Warburg thought this change in metabolism was due to mitochondrial "respiration injury", but this interpretation was questioned by other researchers in 1956 showing that intact and functional cytochromes detected in most tumor cells clearly speak against a general mitochondrial dysfunction.[7] Furthermore, Potter et al. and several other authors provided significant evidence that oxidative phosphorylation and a normal Krebs cycle persist in the vast majority malignant tumors, adding to the growing body of evidence that most cancers exhibit the Warburg effect while maintaining a proper mitochondrial respiration.[6][8] Dang et al.[9] in 2008 provided evidence that the tumor tissue sections used in Warburg's experiments should have been thinner for the oxygen diffusion constants employed, implying that the tissue slices studied were partially hypoxic and the calculated critical diffusion distance was of 470 micrometers.[6] As a result, endless debates and discussions about Warburg's discovery took place and have piqued the interest of scientists all over the world, which has helped bring attention to cell metabolism in cancer and immune cells and the use of modern technology to discover what these pathways are and how they are modified as well as potential therapeutic targets.

Metabolic reprogramming

Simplified view of the aerobic glycolysis (Warburg's effect).

Carcinogenic cells undergo a metabolic rewiring during oncogenesis, and oncometabolites play an important role. In cancer, there are several reprogrammed metabolic pathways that help cells survive when nutrients are scarce:

Aerobic glycolysis, an increase in glycolytic flux, also known as the Warburg effect, allows glycolytic intermediates to supply subsidiary pathways to meet the metabolic demands of proliferating tumorigenic cells.[10] Another studied reprogrammed pathway is gain of function of the oncogene MYC. This gene encodes a transcription factor that boosts the expression of a number of genes involved in anabolic growth via mitochondrial metabolism.[11] Oncometabolite production is another example of metabolic deregulation.[12]

Oncometabolites

Oncometabolites are metabolites whose abundance increases markedly in cancer cells through loss-of-function or gain-of-function mutations in specific enzymes involved in their production, the accumulation of these endogenous metabolites initiates or sustains tumor growth and metastasis.[13] Cancer cells rely on aerobic glycolysis, which is reached through defects in enzymes involved in normal cell metabolism, this allows the cancer cells to meet their energy needs and divert acetyl-CoA from the TCA cycle to build essential biomolecules such as amino acids and lipids.[14] These defects cause an overabundance of endogenous metabolites, which are frequently involved in critical epigenetic changes and signaling pathways that have a direct impact on cancer cell metabolism.[15]

Oncometabolite Role Oncogenes Enzyme affected Associated malignancies References
D-2-hydroxyglutarate
 Inhibits ATP synthase and mTOR signalling IDH1

IDH2

Isocitrate dehydrogenase Brain cancer, Leukemia [15][16][17][13]
Succinate Inhibits 2-oxoglutarate-dependent oxygenase SDHA,SDHB,SDHC,SDHD,SDHAF1,SDHAF2 succinate dehydrogenase Renal and Thyroid tumors [15][13]
Fumarate Inhibits 2-oxoglutarate-dependent oxygenase FH
Fumarate hydratase
 Leiomyomata, Renal cysts [15][16][13]
Glutamine* *(Primary carbon-source for the biosynthesis of the oncometabolite 2-hydroxyglutarate) [18][19]
Sarcosine Activates mTOR signalling pathway GNMT Glycine-N-methyltransferase Pancreatic cancer, Hepatocellular carcinoma [18][20][21][13][22][23]
Asparagine Anti-apoptotic agent ASNS Asparagine synthetase Acute Lymphoblastic Leukemia [18][13][24]
Choline Methyl donor for DNA methylation which disrupts DNA repair PCYT1A phosphate cytidylyltransferase 1 choline-α Breast, Brain and Prostate cancer [18][13][24]
Lactate Induces local immunosuppression LDHA Lactate dehydrogenase A Various types of cancer[25] [13][26]

Epigenetics

Oncometabolite dysregulation and cancer progression are linked to epigenetic changes in cancer cells. Several mechanisms have been linked to D-2-hydroxyglutarate, succinate, and fumarate with the inhibition of α-KG–dependent dioxygenases, this causes epigenetic changes that affect the expression of genes involved in cell differentiation and the development of malignant characteristics.[27] The group of Timothy A. Chan[28] described a mechanism by which abnormal accumulation of the oncometabolite D-2-hydroxyglutarate in brain tumor samples increased DNA methylation, a process that has been shown to play a key role in oncogenesis.[29] On the other hand, in paraganglioma cells, succinate and fumarate were found to methylate histones, effectively silencing the genes PNMT and KRT19, which are involved in neuroendocrine differentiation and epithelial-mesenchymal transition, respectively.[30]

Biomarkers for cancer detection

The discovery of oncometabolites has ushered in a new era in cancer biology, one that has the potential to improve patient care. The discovery of new therapeutic and reliable markers that exploit vulnerabilities of cancer cells, are being used to targeting either upstream or downstream effectors of these pathways.[15] Oncometabolites can be used as diagnostic biomarkers and may be able to assist oncologists in making more precise decisions in early stages of tumorigenesis, particularly in predicting more aggressive tumor behavior.[4]

Isocitrate dehydrogenase

Crystallographic structure of protein isocitrate dehydrogenase.

The detection of D-2-hydroxyglutarate in glioma patients using proton magnetic resonance spectroscopy (MRS) has been shown to be a noninvasive procedure. The presence of IDH1 or IDH2 mutations was linked to the detection of this oncometabolite 100 percent of the time.[31][27] IDH2/R140Q is a specific mutation that has shown promising results after its inhibition by the small molecule AGI-6780.[32] Therefore, limiting the supply of D-2-hydroxyglutarate by inhibiting the detected mutant IDH enzymes could be a good therapeutical approach to IDH-mutant cancers.[33]

Succinate dehydrogenase

IHC staining has been shown to be a useful diagnostic tool for prioritizing patients for SDH mutation testing in early stages of cancer. The absence of SDHB in IHC staining would be linked to the presence of SDH oncogene mutations.[34] The already commercialized drug decitabine (Dacogen®) could be an effective therapy to repress the migration capacities of SDHB-mutant cells,[30]

Fumarate hydratase

IHC staining for FH is used to detect lack of this protein in patients with papillary renal cell carcinoma type 2.[35] The lack of FH in renal carcinoma cells induces pro-survival metabolic adaptations where several cascades are affected.[36]

Glycine-N-methyltransferase

Downregulation of glycine-N-methyltransferase has been linked to hepatocellular carcinoma and pancreatic cancer. Serving this as a reliable marker for oncogenesis.[22] When compared to patients with deletions in GNMT, patients with no deletions early-stage pancreatic cancer had twice the median months overall survival.[23]

Applications

Oncometabolomics

Metabolomics can be applied to oncometabolism, since the changes in cancer's genomic, transcriptomic, and proteomic profiles can result in changes in downstream metabolic pathways. With this information we can elucidate the responsible pathways and oncometabolites for various diseases. Actually, through the use of this technique, the dysregulation of the pyruvate kinase enzyme in glucose metabolism was discovered in cancer cells. Another common used technique is glucose or glutamine labeled with 13C to show that the TCA cycle is used to generate large amounts of fatty acids (phospholipids) and to replenish the TCA cycle intermediates.[37] But oncometabolomics does not necessarily need to be used on cancer cells, but on cells immediately surrounding them in the TME.[38]

Metabolomics applied to cancer has the potential to significantly improve current oncological treatments and has a great diagnostic value, since metabolic changes are the prequel of phenotypic changes in cells (thus tissues and organs) making it suitable for early detection of difficult-to-detect cancers.[14] This also leads to a more personalized medicine and customize an individual's cancer treatment according to their specific oncometabolite profiles, which would allow for better cancer therapy customization or informed adjustments.[13][39]

Software and libraries

Ingenuity Pathway Analysis (IPA)

Ingenuity Pathway Analysis (IPA) is a metabolic pathway analysis software package that helps researchers model, analyze, and comprehend complex biological systems by associating specific metabolites with potential metabolic pathways for data analysis.[40] This software has been used by researchers to elucidate regulatory networks on oncometabolites like hydroxyglutarate.[41]

Metabolights

Metabolights is an open-access database for metabolomics research that collects all experimental data from leading journals' metabolic experiments.[42] Since its initial release in 2012, the MetaboLights repository has seen consistent year-on-year growth. It is a resource that surged in response to the needs of the scientific community to easy access to metabolite data.[43][44]

Research

Transmission electron microscopy of purified exosomes.

Cancer research has been ongoing for centuries, trying to elucidate the origin of its cause. As cancer research evolves with time, the scientific community tends to pay more attention to cell metabolism and how to target these metabolic needs and changes that cells undergo during carcinogenesis.[45] There is growing evidence that metabolic dependencies in cancer are influenced by tissue environment, being this important to consider the TME for different in vitro and in vivo models to study oncometabolism in different cancer scenarios.[46]

There is extensive research on the modulation of BET proteins in cancer models of breast. These proteins appear to be involved in oncometabolism and targeting and uncoupling BRD4 actions in carcinogenic cells, as well as stopping pro-migratory signals and changing cytokine metabolism, particularly IL-6.[47] The same group has reported on the importance of exosomes in the TME and how these vesicles, shed by adipocytes, can carry a specific molecular cargo that causes metabolic changes in the cell, leading to pro-metastatic changes in the recipient breast cancer cells.[48]

References

  1. ^
    S2CID 221807074
    .
  2. ^
    S2CID 229175329
    .
  3. ISBN 978-3-642-74780-9
    .
  4. ^
    S2CID 108294182
    .
  5. PMID 26377897
    .
  6. ^
    S2CID 73502809
    .
  7. PMID 33008042
    .
  8. PMID 27911732
    .
  9. ^ Dang, et al. The interplay between MYC and HIF in cancer. Nature Reviews Cancer volume 8, pages51–56 (2008).
  10. PMID 21985671
    .
  11. doi:10.1158/1557-3125.myc15-ia05
    .
  12. PMID 27386546
    .
  13. ^
    S2CID 5265996
    .
  14. ^
    S2CID 19476401
    .
  15. ^
    PMID 29038145
    .
  16. ^
    PMID 22866264
    .
  17. PMID 20576929
    .
  18. ^
    PMID 31321921
    .
  19. PMID 29056515
    .
  20. PMID 23633921
    .
  21. S2CID 3015270
    .
  22. ^
    S2CID 174817577
    .
  23. ^
    PMID 33802396
    .
  24. ^
    PMID 31998641
    .
  25. PMID 30403008
    .
  26. PMID 26269128
    .
  27. ^
    PMID 23999438
    .
  28. PMID 22343889
    .
  29. PMID 17320506
    .
  30. ^
    PMID 23707781
    .
  31. PMID 22281806
    .
  32. S2CID 9292787
    .
  33. PMID 29458964
    .
  34. PMID 19576851
    .
  35. S2CID 205917783
    .
  36. PMID 31085323
    .
  37. PMID 23063552
    .
  38. PMID 23475953
    .
  39. PMID 26288805
    .
  40. PMID 24924140
    .
  41. PMID 33413208
    .
  42. ^ "MetaboLights - Metabolomics experiments and derived information". www.ebi.ac.uk. Retrieved 2021-11-08.
  43. PMID 31691833
    .
  44. PMID 23109552
    .
  45. PMID 33081387
    .
  46. PMID 28938091
    .
  47. PMID 27651315
    .
  48. S2CID 244529960
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Oncometabolism&oldid=1173356640"